Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
BCL-2 inhibition is a promising therapeutic strategy for small cell lungcancer 30234143 2018 11 14 2331-4737 5 7-8 2018 Jul Oncoscience Oncoscience BCL-2 inhibition is a promising therapeutic strategy for small cell lungcancer. 218-219 10.18632/oncoscience.455 Lochmann Timothy L TL Anthony Faber: Philips Institute for Oral Health Research, Virginia Commonwealth University School of Dentistry and Massey Cancer Center, Richmond, VA, USA. Bouck Ynes M YM Anthony Faber: Philips Institute for Oral (...) Health Research, Virginia Commonwealth University School of Dentistry and Massey Cancer Center, Richmond, VA, USA. Faber Anthony C AC Anthony Faber: Philips Institute for Oral Health Research, Virginia Commonwealth University School of Dentistry and Massey Cancer Center, Richmond, VA, USA. eng Journal Article 2018 08 14 United States Oncoscience 101636666 2331-4737 BCL-2 apoptosis SCLC targeted therapy CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 06 13 2018 06 19
MiRâ€520b restrains cell growth by targeting HDAC4 in lungcancer MicroRNAs (miRNAs) function as tumor promoting or tumor suppressing factors in many cancers. MiR-520b contributes to progression in head-neck and liver cancers, spinal osteosarcoma, and glioma; however, the association of miR-520b with lungcancer progression remains unknown. In this investigation, we explore the effect of miR-520b targeting HDAC4 on lungcancer growth.The regulation of miR-520b or its inhibitor on HDAC4 (...) decrease in HDAC4 expression was observed in lungcancer A549 cells treated with different doses of miR-520b. The miR-520b inhibitor enhanced HDAC4 expression in lungcancer cells. Bioinformatics predicted the targeting of miR-520b on HDAC4. MiR-520b directly targeted the 3' untranslated region of HDAC4. The introduction of miR-520b obviously inhibited cell proliferation in vitro. Anti-miR-520b was capable of accelerating lungcancer cell proliferation; however, HDAC4 knockdown destroyed anti-miR-520b
Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lungcancer? 30116594 2018 11 14 2059-7029 3 5 2018 ESMO open ESMO Open Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lungcancer? e000421 10.1136/esmoopen-2018-000421 Pirker Robert R Department of Medicine I, Medical University of Vienna, Vienna, Austria. eng Editorial 2018 08 10 England ESMO Open 101690685 2059-7029 (...) PD-l1 biomarker immunotherapy predictive factor prognosis Competing interests: RB received honoraria from Merck Sharp Dohme for serving as a member of the Data Monitoring Committee of pembrolizumab trials in lungcancer. 2018 07 16 2018 07 17 2018 8 18 6 0 2018 8 18 6 0 2018 8 18 6 1 epublish 30116594 10.1136/esmoopen-2018-000421 esmoopen-2018-000421 PMC6088342 N Engl J Med. 2015 Oct 22;373(17):1627-39 26412456 N Engl J Med. 2018 Jun 14;378(24):2288-2301 29863955 J Thorac Oncol. 2017 Feb;12(2
Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell LungCancer in the Community Oncology Setting. Broad-based genomic sequencing is being used more frequently for patients with advanced non-small cell lungcancer (NSCLC). However, little is known about the association between broad-based genomic sequencing and treatment selection or survival among patients with advanced NSCLC in a community oncology setting.To compare clinical outcomes (...) ]; P = .40) vs unmatched cohort (hazard ratio, 0.69 [95% CI, 0.62 to 0.77]; log-rank P < .001).Among patients with advanced non-small cell lungcancer receiving care in the community oncology setting, broad-based genomic sequencing directly informed treatment in a minority of patients and was not independently associated with better survival.
Surgically treated lungcancer patients: do they all smoke and would they all have been detected with lungcancer screening? Since publication of the National LungCancer Screening Trial (NLST) results early lungcancer detection has been widely studied, targeting individuals based on smoking history and age. However, over recent decades several changes in lungcancer epidemiology, including risk factors, have taken place. The aim of the current study was to explore smoking prevalence among (...) lungcancer patients who had been treated surgically or undergone a diagnostic operation and whether these patients would have met the NLST inclusion criteria. All patients operated on for lungcancer in a university hospital in Estonia between 2009 and 2015 were included. Data were collected from hospital records. 426 patients were operated on for lungcancer, with smoking history properly documented in 327 patients (87 females; median age 67 years). 170 (52%) patients were smokers, 97 (30
Correlation between radiomic features based on contrastâ€enhanced computed tomography images and Kiâ€67 proliferation index in lungcancer: A preliminary study The purpose of the study was to investigate the association between radiomic features based on contrast-enhanced multidetector computed tomography (CT) and the Ki-67 proliferation index (PI) in patients with lung cancer.One hundred and ten patients with lungcancer confirmed by surgical histology were retrospectively included. Radiomic (...) features were extracted from preoperative contrast-enhanced chest multidetector CT images for each tumor using open-source three-dimensional Slicer software. Statistical analysis was performed to determine significant radiomic features serving as image predictors of Ki-67 status in lungcancer and to investigate the relationship between these features and Ki-67 PI.Higher Ki-67 expression was more common in men (P = 0.02) and patients with a smoking history (P = 0.01). Twelve radiomic features were
Tobacco Dependence Predicts Higher LungCancer and Mortality Rates and Lower Rates of Smoking Cessation in the National Lung Screening Trial Incorporating tobacco treatment within lungcancer screening programs has the potential to influence cessation in high-risk smokers. We aimed to better understand the characteristics of smokers within a screening cohort, correlate those variables with downstream outcomes, and identify predictors of continued smoking.This study is a secondary analysis (...) of the National Lung Screening Trial randomized clinical study. Tobacco dependence was evaluated by using the Fagerstrӧm Test for Nicotine Dependence, the Heaviness of Smoking Index, and time to first cigarette (TTFC); descriptive statistics were performed. Clinical outcomes (smoking cessation, lungcancer, and mortality) were assessed with descriptive statistics and χ2 tests stratified according to nicotine dependence. Logistic and Cox regression models were used to study the influence of dependence
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell LungCancer Purpose The phase III PROFILE 1014 trial compared crizotinib with chemotherapy as first-line treatment in patients with anaplastic lymphoma kinase (ALK) -positive advanced nonsquamous non-small-cell lungcancer. Here, we report the final overall survival (OS) results. Patients and Methods Patients were randomly assigned to receive oral crizotinib (...) that favored crizotinib (hazard ratio, 0.346; 95% bootstrap CI, 0.081 to 0.718). The longest OS was observed in crizotinib-treated patients who received a subsequent ALK tyrosine kinase inhibitor. No new safety signals were identified. Conclusion The final analysis of the PROFILE 1014 study provides a new benchmark for OS in patients with ALK-rearranged non-small-cell lungcancer and highlights the benefit of crizotinib for prolonging survival in this patient population.
Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell LungCancer: A Randomized Phase III NVALT-11/DLCRG-02 Study Purpose The purpose of the current study was to investigate whether prophylactic cranial irradiation (PCI) reduces the incidence of symptomatic brain metastases in patients with stage III non-small-cell lungcancer (NSCLC) treated with curative intention. Patients and Methods Patients with stage III NSCLC-staged with a contrast-enhanced
Incorporating Coexisting Chronic Illness into LungCancer Screening: A Research Statement AMERICANTHORACICSOCIETY DOCUMENTS IncorporatingCoexisting ChronicIllness into Decisionsabout Patient Selection for LungCancer Screening An Of?cial American Thoracic Society Research Statement M. Patricia Rivera, Nichole T. Tanner, Gerard A. Silvestri, Frank C. Detterbeck, Martin C. Tammem¨ agi, Robert P. Young, Christopher G. Slatore, Tanner J. Caverly, Cynthia M. Boyd, Dejana Braithwaite, Joelle T. Fathi (...) -makingwithpatientswhomaynot bene?tfromLCSowingtocoexistingchronicillness.Thisstatement establishesaresearchframeworktoaddressessentialquestions regarding how toincorporateand communicaterisks of comorbiditiesintopatientselectionanddecisionsregardingLCS. Keywords: lungcancer screening; comorbidities; communication of risk Contents Overview Key Conclusions and Recommendations Introduction Methods Results Juxtaposing LungCancer Risk and Competing Risk of Death from Other Causes COPD, LungCancer Risk, Competing Risk
Alectinib hydrochloride (Alecensa) - anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lungcancer (NSCLC) 1 alectinib 150mg hard capsules (Alecensa ® ) SMC2012 Roche Products Limited 6 July 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a full submission assessed under (...) the orphan medicine process alectinib (Alecensa ® ) is accepted for use within NHS Scotland. Indication under review: as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lungcancer (NSCLC). Alectinib, compared with another tyrosine kinase inhibitor, significantly improved progression-free survival in treatment-naïve adults with advanced or recurrent ALK-positive NSCLC. This SMC advice takes account of the benefits
Lungcancer Top results for lungcancer - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lungcancer The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence
Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Nonâ€“Small-Cell LungCancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution Purpose Stereotactic body radiation therapy (SBRT) has emerged as a treatment option for patients with non-small-cell lungcancer (NSCLC). We report the clinical outcomes and toxicity for patients with inoperable primary NSCLC treated with SBRT. Methods Between 2007 and 2015, 102 consecutive lung lesions were treated (...) Most of the 54 patients were men (n = 41; 76%), median age was 75 years; stage IA (n = 36; 66%) and adenocarcinoma (n = 43; 80%) were the most common stage and histologic diagnosis, respectively. Five patients had two lung lesions. A median of three fractions (range, 3 to 5 fractions) and a total median dose of 54 Gy (range, 45 to 60 Gy) per lesion were prescribed. The median follow-up was 17.8 months (range, 4 to 56.4 months). The 2-year rates of LC, regional or distant failure-free survival